Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer

Sichuan Provincial People's Hospital

Status and phase: Unknown; Phase 2

Conditions: Neoadjuvant Therapy; Colorectal Cancer

Treatments: Drug: FOLFOX regimen; Drug: apatinib and FOLFOX regimen

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03377842

APTN-CRC-201712

Details and patient eligibility

About

Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and to explore factors associated with efficacy.

Full description

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition.Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the CFDA in 2017.

Apatinib, a small molecule receptor tyrosine kinase (RTK) inhibitor, targets the intracellular domain of the VEGFR-2 ATP binding site, and is the first anti-angiogenic therapy approved by the China Food and Drug Administration in December 2014 for the treatment of metastatic gastric cancer in third-line or later treatment. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. It is an investigational cancer drug currently undergoing clinical trials as a potential targeted treatment for metastatic gastric carcinoma, metastatic breast cancer ,advanced hepatocellular carcinoma and advanced colorectal cancer.

Apatinib are often used in advanced colorectal cancer for uses that are not within its approved indication for use.However, the knowledge gained from all uses of apatinib in this medical practice is often not realized because the data collected are not systematically characterized, aggregated, and analyzed in a way that can be relied upon to inform its further usage.

In some cases, a "traditional" clinical trial may be impractical or excessively challenging to conduct. Ethical issues regarding treatment assignment, and other similar challenges, may present themsevels when developing and attempting to execute a high quality clinical trial. Analyses of real-world data(RWD), using appropriate methods, may in some cases provide similar information with comparable or even superior characteristics to information collected and analyzed through a traditional clinical trial. For example, RWD collected using a randomized exposure assignment within a registry can provide a sufficient number of patients for powered subgroup analyses.

the investigators will evaluate the efficacy and safety for Apatinib combine with other chemotherapy regimens as the neoadjuvant therapy in advanced colorectal cancer in a real world study setting. This study leveraging RWD can potentially provide information on a wider patient population, thus providing information that cannot be obtained through a traditional clinical trial alone.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of 18 years or older.
• Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum;
• Stage TxNxM1 (truly metastatic disease) with liver metastases only.
• Patients should be voluntary to the trial and provide with signed informed consent.
• The researchers believe patients can benefit from the study.

Exclusion criteria

• Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.
• Pregnant or lactating women
• Patients with Apatinib contraindications
• Patients of doctors considered unsuitable for the trial

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

FOLFOX regimen

Active Comparator group

Description:

FOLFOX regime alone.

Treatment:

Drug: FOLFOX regimen

Apatinib and FOLFOX regimen

Experimental group

Description:

Apatinib combine with FOLFOX regimen.

Treatment:

Drug: apatinib and FOLFOX regimen